Skip to content
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Publication Details
AFRICAN RESEARCH NEXUS
SHINING A SPOTLIGHT ON AFRICAN RESEARCH
medicine
Virologic response at week 8 of combined treatment as a predictor of sustained virologic response in non rapid virologic response, chronic HCV genotype 4 infected patients
Egyptian Journal of Medical Human Genetics, Volume 13, No. 3, Year 2012
Notification
URL copied to clipboard!
Description
Optimization of interferon-based treatment regimens remains an important goal as pegylated interferon is likely to remain the backbone of chronic HCV treatment in the foreseeable future. The objective of the current study was to evaluate virological response at week 8 of combined treatment as a predictor of sustained virologic response (SVR) in non rapid virologic response (RVR), chronic HCV genotype 4 infected patients. A total of 38 patients with chronic HCV genotype 4 infection were enrolled in the study. All patients received a combination of pegylated interferon α-2a plus ribavirin. Virological response at week 8 of combined treatment was evaluated as a predictor of SVR. Week 8 response was more sensitive but less specific than RVR in predicting SVR, in non RVR patients (24 patients), week 8 response had a sensitivity of 45.5% and a specificity of 76.9% for predicting SVR. In conclusion: In non RVR patients, measurement of HCV RNA at week 8 is an optimal time to identify those who are not going to benefit from pegylated interferon and ribavirin combination therapy. © 2012.
Authors & Co-Authors
Monis, Ali
Egypt, Cairo
Faculty of Medicine - Ain Shams University
Ali Monis, Ahmed
Egypt, Cairo
Faculty of Medicine - Ain Shams University
Al Swaff, Reham Ezzat
Egypt, Cairo
Faculty of Medicine - Ain Shams University
Statistics
Citations: 3
Authors: 3
Affiliations: 1
Identifiers
Doi:
10.1016/j.ejmhg.2012.03.002
e-ISSN:
20902441
Research Areas
Genetics And Genomics